Please find enclose statement of deviation(s) or variation(s).

-, :t POLYMED Poly Medicure Limited I Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi -110 020 (INDIA) T: +91-11-33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN: L40300DL l 995PLC066923 Date: 05111 November, 2026 Scrip Code: -531768 Scrip Code:- POLYMED The Manager, The Manager BSE Limited, National Stock Exchange of India Limited Department of Corporate Services, Exchange Plaza, Plot No. C/1-Block-G Phirozee Jeejeebhoy Towers, Sandra Kurla Complex, Bandra(E), Dalal Street, Mumbai-400001. Mumbai-400051. Reg: -Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"). Subject: - Statement of deviation(s) or variation(s), if any, of utilization of proceeds received from Qualified Institutions Placement (QIP). Dear Sir/Madam, We would like to inform that the Company had raised funds by way of allotment of 53,19,148 (Fifty Three Lakh Nineteen Thousand One Hundred Forty Eight) equity shares of face value of Rs. 5/- each, to qualified institutional buyers ("QIBs"), at a price of Rs. 1880/- per Equity Share (including premium of Rs. 1875/- per Equity Share), pursuant to the resolution passed by the Board of Directors dated 29th June, 2024, special resolution passed by the Shareholders thrnugh postal ballot on 5th August, 2024, the preliminary placement document dated 19th August, 2024, the placement document dated 22nd August, 2024 and resolution of lhc QIP Committee of the Board of Directors dated 22nd August, 2024 (the "Issue"). We would further Like to inform that the Audit Committee, at its meeting held on November 05, 2026, has reviewed the actual utilization of funds received for an amount aggregating ~Rs 99,999.98 lakh, pursuant to the Issue. In this connection, we submit that there is no deviation or variation from the objects of the Issue, in the utilization of proceeds, as stated in the placement document, during the quarter ended September 30, 2026. In terms of Regulations 32(1), 32(2) and 32(3) of the SEI3I Listing Regulations, a statement of deviation or variation, if any, in utilization of funds raised through Qualified Institutions Placement (QlP), for the quarter ended September 30, 2026, duly reviewed by the Audit Committee, in the prescribed format is also enclosed herewith This is for your information and l'Ccord. For Poly Medicure Limited Avinash Chandra Company Secretary M. No. A32270 Plants: Plot No. l 04-105 & 115-116-117, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad -121004, Haryana (INDIA) Plot No. 33-34, Sector-68, IMT, Faridabad-121004, (Haryana) INDIA T:+91-129-4287000, 3355070 Statement of Deviation/Variation in utilization of funds raised Name of listed entity !Poly Medicure Limited !Mode of Fund Raising Qualified Institutions Placement (QIP) !Date of Raising Funds ~ssue Open Date :19.08.2024 ~ssue Closing Date :22.08.2024 !Date of allotment of equity shares: 22.08.2024 !Amount Raised !Rs 99,999.98 lakh (approx.) !Report filed for Quarter ended September 30, 2026 Monitoring Agency !Applicable Monitoring Agency Name, if applicable CRISIL Ratings Limited s there a Deviation / Variation in use of funds raised No nf yes, whether the same is pursuant to change in terms of a contract Not Applicable pr objects, which was approved by the shareholders f Yes, Date of shareholder Approval !Not Applicable Explanation for the Deviation/ Variation !Not Applicable Comments of the Audit Com,rnittee after review No comments ~omments of the auditors, if any No comments Objects for which funds have been raised and where there has been a deviation, in the following table Original Object !Modified Original Modified !Funds !Amount of !Remarks if any Object, if IAilocation allocation, if IU tilize d till !Deviation/ any (Amount in any (Amount September Iv ariation for llakhs) in Lakhs) ~o, 2026 lhe quarter (Amount in according to llakhs) applicable lobject (a) Funding capital expenditure to be N.A. 49,973.16 N.A. 9,544.62 N.A. No Deviation !incurred by Company for setting up of !manufacturing facilities. (b)Pursuing inorganic initiatives N.A. 25,026.84 N.A. 25,026.84 N.A. No Deviation (c) General corporate purposes N.A. 23,534.37 34.39 23,534.37 N.A. No Deviation ri'otal 98,534.37 34.39 58,105.83 *(net of **(Modified issue allocation) expenses) i><-The actual issue proceeds come to ~Rs.99,999.98 lakh and as per placement document, the expenses related to the issue were ~stimated at Rs. 1500 Lakhs whereas after meeting all the QIP expenses, the same has come to Rs 1,465.61 lakh. Remainin~ $urplus of Rs 34.39 lakh from issue expenses is added to the GCP, accordingly cost of GCP is revised from Rs 23,499.98 lakl, as mentioned in the placement document to Rs 23,534.37 lakh. Accordingly, the balance unutilized Rs 98,534.37 Lakhs werE already transferred to the Monitoring Account on Rs 98,534.37 Lakhs. 1t*During the quarter ended March 31, 2025, the actual utilization of issue-related expenses was lower than the estimated amount disclosed in the placement document, resulting in a surplus of Rs. 34.39 lakh. This surplus was adjusted against the K:;CP object, which increased the GCP amount to Rs. 23,534.37 lakh and, consequently increased the net proceeds amount to IRs. 98,534.37 lakh. Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or b) Deviation in the amount·of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc. Nar Vijayvergiya Chief Financial Officer Date: 05.11.2026